Secondary outcomes 1. Mean xerostomia inventory score [23]; 2. Oral health related quality of life; 3. Adverse events (according to NCI Common Terminology for Adverse Events [24]); 4. Dysphagia (Ponatinib difficulty swallowing); 5. Dysgeusia (distortion of taste); 6. Global impression

of change. The trial will be reported according to the Consort statement [25], and analysis will be on an intention-to-treat basis. Patient assessment 1. Outcome Measures The schedule of assessments is presented in Table 1. The outcome measures assess different aspects of the trial as follows: Table 1 Schedule of Inhibitors,research,lifescience,medical assessments (a) Response to pilocarpine: (i) Numerical rating scale (NRS) for xerostomia. The NRS consists of a range of numbers, with the smaller numbers indicating less dry mouth. An 11-point NRS rates symptom intensity corresponding to an integer number between 0 and 10. People rate their dry mouth by marking a number Inhibitors,research,lifescience,medical on a paper that lists the numbers horizontally in ascending order. The NRS has well-established psychometric properties; being valid, reliable, and sensitive to change. It is nonintrusive, easy to administer and score, and suitable for repeated use [26]. Although no studies were found on the psychometric properties of NRS in xerostomia, NRS are commonly used in studies of this condition. Severity of xerostomia will be measured using Inhibitors,research,lifescience,medical a 0-10 cm NRS ranging

from 0=no dry mouth to 10=worst possible dry mouth. At each assessment point, patients will be asked to score their current, worst, best and average dry mouth score over the preceding 24 hours. Dysphagia and dysgeusia (a distortion of Inhibitors,research,lifescience,medical the sense of taste) scores will also be recorded

in a daily diary using a 0-10mm NRS. (i) The xerostomia inventory (XI) [23], a valid and reliable scale for measuring xerostomia symptoms, will also be used as a secondary measure. (a) Performance status: Australian Karnofsky Performance Scale (AKPS) [27]. This scale assesses functional performance and is a validated modification of the gold-standard Inhibitors,research,lifescience,medical Karnofsky Performance Scale, altered to apply to both community and hospital patients. It has high test-retest reliability, high predictability of survival time, and sensitivity to change towards the end of life. (a) Presence of side-effects: Any toxicity will be rated using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTC AE) v3.0 [24]. The trial will be overseen below by an independent data safety monitoring committee. (a) Quality of life (QOL) indicators: (i) EORTC-QLQC15-PAL core items [28], is a general cancer QOL questionnaire suited to a palliative sample as it yields data on overall QOL, physical, emotional and social functioning and other symptoms, has been extensively validated, has reference data available and uses standardised scoring procedures, with evidence concerning interpretation of scores.